Defunct Company
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
88
NCT04471415
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 31, 2020
Completion: Mar 28, 2023
NCT06027086
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Role: Collaborator
Start: Feb 12, 2024
Completion: Sep 1, 2033